Manufacturing & Production
SpectrumX upgrades facilities to kickstart clinical trial programme
SpectrumX have announced recent changes to their state-of-the-art production facility in Knutsford, Cheshire. This has paved the way towards the production of its drug substance, SPC-069, for clinical trials, according to Proactive Investors.
The upgrades to the facility included an ISO Class 8 Cleanroom, which includes a best-in-class air purification, ventilation, and pressurecascade system to prevent air contaminants during manufacturing processes.
Other facilities that have been added include a dedicated quality control room and a microbiology laboratory, which tests all raw materials, key manufacturing steps, and finished cosmetic and biocide products. SpectrumX can now begin preparations for a clinical trial programme to take its novel respiratory treatment,
SPX-001, to market.
Ben Hibbert, SpectrumX’s operations director, said: “We are delighted our Knutsford facility now meets the standards required for the production of a pharmaceutical drug substance - in our case, SPC-069.
“To achieve this, we installed equipment across the facility and introduced new operating procedures. This is a significant step for the business as it allows us to kickstart our clinical trial programme. We now have the right environment to create and distribute our full range of hypochlorous acid products, which we believe will be gamechangers in the market.”
Manufacturing in the UK provides SpectrumX with supply chain and production facilities which are not available when shipping product from California.